Literature DB >> 15084755

Visualization and quantitation of peroxisomes using fluorescent nanocrystals: treatment of rats and monkeys with fibrates and detection in the liver.

H M Colton1, J G Falls, H Ni, P Kwanyuen, D Creech, E McNeil, W M Casey, G Hamilton, N F Cariello.   

Abstract

Peroxisome proliferation in the liver is a well-documented response that occurs in some species upon treatment with hypolipidemic drugs, such as fibrates. Typically, liver peroxisome proliferation has been estimated by direct counting via electron microscopy, as well as by gene expression, enzyme activity, and immunolabeling. We have developed a novel method for the immunofluorescent labeling of peroxisomes, using an antibody to the 70-kDa peroxisomal membrane protein (PMP70) coupled with fluorescent nanocrystals, Quantum Dots. This method is applicable to standard formalin-fixed, paraffin-embedded tissues. Using this technique, a dose-dependent increase in PMP70 labeling was evident in formalin-fixed liver sections from fenofibrate-treated rats. In formalin-fixed liver sections from cynomolgus monkeys given ciprofibrate, quantitative image analysis showed a statistically significant increase in PMP70 labeling compared to control; the increase in hepatic PMP70 protein levels was corroborated by immunoblotting using total liver protein. An increase in hepatic peroxisome number in ciprofibrate-treated monkeys was confirmed by electron microscopy. An advantage of the Quantum Dot/PMP70 method is that a single common protocol can be used to label peroxisomes from several different species, and many of the common problems that arise with immunolabeling, such as fading and low signal strength, are eliminated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084755     DOI: 10.1093/toxsci/kfh144

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  8 in total

1.  Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats.

Authors:  Vivian Boshra; Amal M Moustafa
Journal:  J Mol Histol       Date:  2011-02-09       Impact factor: 2.611

Review 2.  Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-11-19       Impact factor: 4.481

Review 3.  Effects of nanomaterial physicochemical properties on in vivo toxicity.

Authors:  Kristin L Aillon; Yumei Xie; Nashwa El-Gendy; Cory J Berkland; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2009-04-20       Impact factor: 15.470

Review 4.  Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance.

Authors:  Stephan Kemp; Frederica L Theodoulou; Ronald J A Wanders
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Tissue-specific differential induction of duplicated fatty acid-binding protein genes by the peroxisome proliferator, clofibrate, in zebrafish (Danio rerio).

Authors:  Ananda B Venkatachalam; Santosh P Lall; Eileen M Denovan-Wright; Jonathan M Wright
Journal:  BMC Evol Biol       Date:  2012-07-09       Impact factor: 3.260

Review 6.  A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors.

Authors:  Ron Hardman
Journal:  Environ Health Perspect       Date:  2006-02       Impact factor: 9.031

7.  Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3.

Authors:  Vrathasha Vrathasha; Karl Booksh; Randall L Duncan; Anja Nohe
Journal:  Nanomaterials (Basel)       Date:  2018-07-09       Impact factor: 5.076

Review 8.  Potential clinical applications of quantum dots.

Authors:  Igor L Medintz; Hedi Mattoussi; Aaron R Clapp
Journal:  Int J Nanomedicine       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.